Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis- Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 18, Issue 4, 2007, Pages 241-248

  Gold, Ronald ^a   Barreto, Luis ^b,f   Ferro, Santiago ^b   Thippawong, John ^b   Guasparini, Roland ^c   Meekison, William ^d   Russell, Margaret ^e   Mills, Elaine ^b   Harrison, Dana ^b   Lavigne, Pierre ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Sanofi Pasteur   (Canada)

^c Boundary Health Unit   (United Kingdom)

^d SIMON FRASER UNIVERSITY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f NONE   (Canada)

Author keywords

Acellular pertussis vaccine; Combination vaccine; Diphtheria toxoid; Haemophilus influenzae type b conjugate vaccine; Inactivated polio vaccine; Tetanus toxoid

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VIRUS VACCINE; PEDIACEL; POLIOMYELITIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DIPHTHERIA; DRUG SAFETY; EATING DISORDER; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; TETANUS; VACCINATION; VOMITING;

EID: 34948840372     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/289842     Document Type: Article

References (50)

1. Thipphawong J, Barreto L, Mills E, et al. A fully-liquid, acellular pertussis vaccine combined with IPV and Hib vaccines (DTaP-IPV-Hib) is safe and immunogenic without significant interactions (Workshop W3E). International Conference on Acute Respiratory Infections. Canberra, July 7 to 10, 1997.
2. Mills E, Russell M, Cunning L et al. A fully liquid acellular pertussis vaccine combined with IPV and Hib vaccines (DTaP-IPV-Hib) is safe and immunogenic without significant interactions. Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Sept 28 to Oct 1,1997.
3. Mills E, Russell M, Cunning L, et al. Comparative immunogenicity of an acellular pertussis-inactivated polio (DTaP-IPV) vaccine used to reconstitute lyophilized H influenzae b (PRP-T) or licensed DTwP-IPV-PRP-T vaccine in infants. Society for Pediatric Research, Washington DC, May 2 to 6, 1997.
4. Mills E, Xie F, Gold R, Harrison DL. Immune responses to inactivated polio vaccines in combination with other vaccines. Infectious Disease Society of America 39th Annual Meeting, San Francisco, Oct 25 to 28, 2001.
5. Halperin SA, Barreto L, Eastwood BJ, Law B, Roberts EA. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med 1994;148:1220-4.
6. Halperin SA, Mills E, Barreto L, Pim C, Eastwood BJ. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1995;14:792-7.
7. Halperin SA, Eastwood B, Barreto L, et al. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis 1995;27:279-87.
8. Halperin SA, Eastwood BJ, Barreto L, et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine 1996;14:767-72.
9. Halperin SA, Barreto L, Eastwood BJ, et al. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine 1997;15:295-300.
10. Halperin SA, Davies HD, Barreto L, et al. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr 1997;130:525-31.
11. Anderson EL, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccine combined with diphtheria and tetanus in infants. J Infect Dis 1988;157:731-7.
12. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. J Pediarr 1991;119:194-204.
13. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: Adverse reactions. Pediatrics 1995;96:557-66.
14. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: Overview and serologic response. Pediatrics 1995;96:548-57.
15. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 1996;150:457-60.
16. Black SB, Shinefield HR, Bergen R, et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatr Infect Dis J 1997;16:53-8.
17. Miller E, Ashworth LA, Redhead K, Thornton C, Waight PA, Coleman T. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance. Vaccine 1997;15:51-60.
18. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr 1996;129:695-701.
19. Schmitt HJ, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997;130:616-23.
20. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1981;1:955-60. (Erratum in 1988;1:1238).
21. Storsaeter J, Blackwelder WC, Hollander HO. Pertussis antibodies, protection and vaccine efficacy after household exposure. Am J Dis Child 1992;146:167-72.
22. Trollfors B, Tarranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
23. Greco D, Salmaso S, Mastrantonio T, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996;334:341-8.
24. Gustafsson L, Hallander HO, Olin P, Reizensrein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55. (Etratum in 2;334:1207).
25. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997;350:1569-77. (Erratum in 1998;351:454).
26. Schmitt HJ, von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
27. Taranger J, Trollfors B, Lagergård T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997;16:180-4.
28. Trollfors B, Taranger J, Lagergård T, et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J Pediatr 1997;130:532-6.
29. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12.
30. National Advisory Committee on Immunization. Statement on pertussis vaccine. Can Commun Dis Rep 1997;23:1-16.
31. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants and two, fout and six months of age. Vaccine 1998;16:576-85.
32. Halperin SA, McDonald J, Samson L, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: A randomized controlled trial. Clin Invest Med 2002;25:243-51.
33. Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP-IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 2006;24:2057-64.
34. Galanis E, King AS, Varughese P, Halperin SA; IMPACT investigators. Changing epidemiology and emerging risk groups for pertussis. CMAJ 2006;174:451-2.
35. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S; Canadian Paediatric Society/ Health Canada Immunization Monitoring Program-Active (IMPACT). Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: A report from IMPACT. Pediatrics 2003;112:e348.
36. Scheifele D, Halperin S, Law B, et al; Canadian Paediattic Society / Health Canada Immunization Monitoring Program, Active. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ 2005;172:53-6.
37. Donaldson L, Mullaly S, Smith J. New vaccinations for the childhood immunisation programme. 〈http://www.dh.gov.uk/en/Publicationsandstatistics/ Lettetsandcirculars/Professionalletters/Chiefpharmaceuticalofficerletters/ DH_4087350〉 (Lett)
38. Schmitt HJ, Zepp F, Muschenborn S, et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998;157:208-14.
39. Pichichero ME, Latiolais T, Bernstein DI, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J 1997;16:863-70.
40. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996;348:1688-92.
41. Amir J, Melamed R, Bader J, et al. Immunogenicity and safety of a liquid combination of DTP-PRP-T [corrected] vs lyophilized PRP-T reconstituted with DTP. Vaccine 1997;15:149-54. (Erratum in 1997;15:1813).
42. National Advisory Committee on Immunization. Canadian Immunization Guide, 4th edn. Ontario: Health Canada, 1993:87-9.
43. Manclark CR, Meade BD, Burstyn, DG. Serological response to Bordetella pertussis. In: Eds Rose, NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology, 3rd edn. Washington DC: American Society of Microbiology,1986:388-94.
44. Ipp MM, Gold R, Goldbach M, et al. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: Effect of injection site and needle length. Pediatrics 1989;83:679-82.
45. Castañeda JL, Gonzalez N, Lavigne P, Ortiz E. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine with full primary IPV or sequential IPV-OPV in Mexican infants. Int J Infect Dis 2004;8:S71. (Abst)
46. Lin TY, Wang YH, Chang LY, et al. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine: Immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis 2007;11:129-36.
47. National consensus conference on pertussis, Toronto, May 25-28, 2002. Can Commun Dis Rep 2003;29(Suppl 3):1-36.
48. Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007;26:31-5.
49. Halperin SA, De Serres G. Has the change from acellular to pertussis vaccine improved or worsened pertussis control? CMAJ 2006;175:1227.
50. Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently of combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J 1994;13:348-55.